HIV 治療藥物市場規模、佔有率和成長分析：按藥物類別、分銷管道和地區分類 - 產業預測，2024-2031 年

HIV Drugs Market Size, Share, Growth Analysis, By Drug Class, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年07月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年HIV治療市場規模為309.9億美元，從2023年的322.6億美元增加至2031年的444.9億美元，預計複合年成長率為4.10%。

HIV膠囊市場是製藥業的重要組成部分，為愛滋病毒/愛滋病患者提供挽救生命的治療。由於醫療技術的進步和愛滋病毒預防和治療意識的提高，該市場正在經歷顯著成長。促成這一成長的因素包括愛滋病毒/愛滋病發病率上升、醫療保健服務範圍擴大以及研究和發展力度加大。該市場主要由抗逆轉錄病毒療法（ART）的需求驅動，抗逆轉錄病毒療法可減少病毒量、改善免疫功能並預防病毒感染。受愛滋病毒/愛滋病盛行率上升（特別是在發展中國家）以及新的更有效愛滋病毒治療方法開發的影響，預計該市場將在 2022 年和 2023 年保持上升趨勢。長效注射療法等技術進步預計也將塑造市場。儘管 COVID-19 大流行造成了干擾，但仍在努力確保愛滋病毒治療和預防服務的連續性。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Gilead Sciences Inc.（United States）
ViiV Healthcare（United Kingdom）
Merck & Co., Inc.（United States）
GlaxoSmithKline plc（United Kingdom）
Bristol Myers Squibb（United States）
Johnson & Johnson（United States）
AbbVie Inc.（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Boehringer Ingelheim（Germany）
Cipla Ltd（India）
Mylan NV（Netherlands）
Teva Pharmaceutical Industries Ltd（Israel）
Pfizer Inc.（United States）
Aurobindo Pharma Limited（India）
Sun Pharmaceutical Industries Ltd（India）
Lupin Pharmaceuticals, Inc.（India）
Hetero Drugs Limited（India）
Emcure Pharmaceuticals Limited（India）
Aspen Pharmacare Holdings Limited（South Africa）
Theratechnologies Inc.（Canada）

簡介目錄

Product Code: SQMIG35I2310

HIV Drugs Market size was valued at USD 30.99 billion in 2022 and is poised to grow from USD 32.26 billion in 2023 to USD 44.49 billion by 2031, growing at a CAGR of 4.10% during the forecast period (2024-2031).

The HIV capsules market is a crucial segment of the pharmaceutical industry, providing life-saving treatments for individuals living with HIV/AIDS. The market has experienced significant growth due to advancements in medical technology and increased awareness of HIV prevention and treatment. Contributing factors to this growth include the rising incidence of HIV/AIDS, greater access to healthcare services, and ongoing research and development. The market is primarily driven by the demand for antiretroviral therapy (ART), which reduces viral load, improves immune function, and prevents virus transmission. The market is expected to continue its upward trajectory in 2022 and 2023, influenced by the increasing prevalence of HIV/AIDS, particularly in developing countries, and the development of new and more effective HIV medications. Technological advancements, such as long-acting injectable treatments, are also expected to shape the market. Despite disruptions caused by the COVID-19 pandemic, efforts are being made to ensure continuity in HIV treatment and prevention services.

Top-down and bottom-up approaches were used to estimate and validate the size of the HIV Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

HIV Drugs Market Segmental Analysis

The HIV Drugs market is segmented based on drug class, distribution channel, and region. Based on drug class, the market is segmented into Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Inhibitors, Entry Inhibitors, and Fixed-Dose Combinations. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on Region, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Drivers of the HIV Drugs Market

The persistent global prevalence of HIV/AIDS drives a sustained demand for antiretroviral drugs, bolstered by government initiatives and international funding, particularly in developing countries, which enhance accessibility. The Asia-Pacific region is experiencing the highest growth rate in the market due to improved health awareness, better healthcare infrastructure, and an increase in hospitals and ambulatory surgical centers equipped with advanced medical facilities. Ongoing research and development activities lead to the discovery of new and more effective antiretroviral drugs, further stimulating market expansion. Additionally, rising awareness and proactive testing initiatives contribute to early detection, increasing the demand for HIV medications. Collaborations among governments, non-profits, and pharmaceutical companies worldwide aim to address HIV/AIDS challenges, fostering market growth.

Restraints in the HIV Drugs Market

Limited access to HIV medications, particularly in developing regions, poses a significant challenge. Affordability issues can hinder patients' ability to obtain essential drugs. Stigma surrounding HIV/AIDS in various societies can impede awareness campaigns, discourage testing, and prevent patient adherence to treatment regimens. The availability of generic versions of some HIV medications challenges market sales, especially in areas where cost-effectiveness is crucial. Inadequate healthcare infrastructure, particularly in developing countries, restricts the effective distribution and administration of HIV drugs, impacting market growth. Additionally, the emergence of drug-resistant HIV strains challenges the effectiveness of existing antiretroviral drugs, necessitating ongoing research and development efforts.

Market Trends of the HIV Drugs Market

There is a trend toward the development and adoption of single-tablet regimens (STRs) that combine multiple antiretroviral drugs into one pill, simplifying treatment, improving adherence, and enhancing patient convenience. Research is focusing on long-acting antiretrovirals (ARVs), including injectables, to reduce administration frequency and improve adherence and treatment outcomes. Pre-exposure prophylaxis (PrEP) is expanding with new formulations like tenofovir alafenamide (TAF) and emtricitabine to lower HIV transmission risk. Innovative drug delivery systems, such as implants and patches, are being explored to offer alternative administration methods and potentially improve adherence. There's an increasing focus on pediatric HIV treatment, with efforts to develop child-friendly formulations and dosages. Novel combinations of antiretroviral drugs are being explored to enhance efficacy, reduce side effects, and address drug resistance. Digital health solutions, including telemedicine and mobile apps, are being integrated to monitor adherence, provide education, and improve healthcare management for individuals with HIV. Emphasis on drug resistance monitoring is growing through surveillance programs and research to mitigate resistance development. Global health initiatives aim to improve access to antiretroviral medications in low- and middle-income countries, contributing to global goals like UNAIDS 95-95-95. Pharmaceutical companies and global health organizations are working on programs to enhance the affordability and accessibility of HIV drugs through voluntary licensing agreements and access initiatives. Research into novel drug classes beyond traditional antiretrovirals focuses on improving treatment outcomes and reducing side effects. Community engagement and patient advocacy are increasingly recognized as crucial in shaping treatment guidelines, research priorities, and access initiatives.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Start-up Analysis
Regulatory Landscape
Raw Material Analysis
Supply Chain Analysis
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

HIV Drugs Market by Drug Class

Market Overview
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Integrase Inhibitors
Entry Inhibitors
Fixed-Dose Combinations

HIV Drugs Market by Distribution Channel

Market Overview
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

HIV Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Gilead Sciences Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViiV Healthcare (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals, Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hetero Drugs Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emcure Pharmaceuticals Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Pharmacare Holdings Limited (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theratechnologies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments